Loading...
•
Dec 31, 2023
Lipocine Q4 2023 Earnings Report
Reported financial results for the year ended December 31, 2023.
Key Takeaways
Lipocine reported a net loss of $16.4 million, or ($3.14) per diluted share, for the year ended December 31, 2023, compared with a net loss of $10.8 million, or ($2.15) per diluted share, for the year ended December 31, 2022. As of December 31, 2023, Lipocine had $22.0 million of unrestricted cash, cash equivalents and marketable investment securities compared to $32.5 million at December 31, 2022.
Net loss for the year ended December 31, 2023 was $16.4 million, or ($3.14) per diluted share.
Recognized a non-cash minimum guaranteed royalties reversal of variable consideration revenue of $2.9 million related to the termination of the Antares License Agreement.
Research and development expenses were $10.2 million for the year ended December 31, 2023.
As of December 31, 2023, Lipocine had $22.0 million of unrestricted cash, cash equivalents and marketable investment securities.
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...